NP/PA Connect
News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|March 28, 2025

Laboratory Monitoring with Oral JAK Inhibitors

Author(s)Lisa Swanson, MD, FAAD, Linda Stein Gold, MD, James Song, MD, FAAD

Panelists discuss how to implement and maintain appropriate laboratory monitoring protocols when prescribing oral JAK inhibitors, ensuring patient safety through regular assessment of key clinical parameters.

Episodes in this series

4 experts are featured in this series.

EP. 1 Determining Atopic Dermatitis Severity and When to Advance to Systemic Therapy

4 experts are featured in this series.

EP. 2 Optimizing Disease Control and AAD Guidelines for Systemic Therapies

4 experts are featured in this series.

EP. 3 Selecting Systemic Therapy for Patients with Moderate to Severe Atopic Dermatitis

4 experts are featured in this series.

EP. 4 The JAK-STAT Signaling Pathway and Its Role in Atopic Dermatitis

4 experts are featured in this series.

EP. 5 The Impact of JAK Selectivity in Atopic Dermatitis Treatment

4 experts are featured in this series.

EP. 6 Efficacy, Safety, and Role in Therapy of JAK Inhibitors for Atopic Dermatitis

4 experts are featured in this series.

EP. 7 Navigating the Boxed Warning for the JAK Inhibitor Class

4 experts are featured in this series.

EP. 8 Talking to Patients About the Safety of JAK Inhibitors in Atopic Dermatitis

4 experts are featured in this series.

EP. 9 Laboratory Monitoring with Oral JAK Inhibitors

4 experts are featured in this series.

EP. 10 Differentiating Between JAK Inhibitors in Clinical Practice

4 experts are featured in this series.

EP. 11 Overcoming Therapeutic Inertia in a 25-Year-Old Man with Moderate to Severe Atopic Dermatitis

4 experts are featured in this series.

EP. 12 Switching from Biologics to JAK Inhibitors in Nonresponders and Dose Escalation

4 experts are featured in this series.

EP. 13 Navigating Patient Factors When Deciding Treatment for a 38-Year-Old Woman With Severe Atopic Dermatitis

4 experts are featured in this series.

EP. 14 Determining Appropriate Candidates for JAK Inhibitor Therapy

4 experts are featured in this series.

EP. 15 Utility of Head-to-Head Studies in Atopic Dermatitis and Future Research Directions

EP. 16 Advancing Atopic Dermatitis Treatment by Understanding the Role of Multitargeted Therapies

EP. 16 Advancing Atopic Dermatitis Treatment by Understanding the Role of Multitargeted Therapies

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

In-Person Event

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

February 7, 2026

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Trending on Dermatology Times

Kyowa Kirin Takes Full Control of Rocatinlimab Program

Dermatology Times January 2026 Recap

The Weekly Roundup: January 26-30

The Rx Recap: January 25-30

Galderma Prioritizes Menopause-Related Skin Health with New Data at IMCAS 2026